July 2016 PMID 27299675

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman

Full text PDF Download social card

Mentions

Peak: 1 in Jun 2016

across 5 sources since Jun 2016

Extended reach

9,803

potential audience

Total likes

106

Video views

9,804

Mentions per month

Jun 2016 – Aug 2021

Where it's discussed

News29 articles
Facebook22 posts
Blogs8 articles
YouTube2 videos
Bluesky1 posts

AI synopsis

What people are saying

The discussions mainly revolve around anticipation for future coverage, such as the upcoming discussion by #NephJC, with no detailed critique or personal insights. The tone suggests curiosity rather than strong engagement or debate, which contributes to the neutral scores.

AgreementNeither agree nor disagree

The discussion appears neutral, with no strong consensus either for or against the publication's findings.

InterestModerate interest

Participants show a mild interest, primarily noting upcoming coverage and general topics without deep analysis.

EngagementNeutral engagement

The responses are minimal, mostly brief mentions and plans to explore the topic, indicating limited in-depth discussion.

ImpactNeutral impact

The overall group does not demonstrate signs of high-impact or significant influence from the publication.

All mentions

ESC Guidelines for Heart Failure Management Explained by Prof. Maack

Professor Christoph Maack from Würzburg discusses new ESC guidelines for heart failure published on August 27, 2021. He also elaborates on the EMPEROR-Preserved study regarding Empagliflozin therapy for heart failure…

MARKUS at HOMe · Aug 28, 2021 7,547 views

KDIGO Guidelines for Diabetes and CKD Management with EMPA-Kidney Study Insights

Professor Christoph Wanner summarizes key elements of the KDIGO 2020 guidelines for diabetes management in chronic kidney disease, discussing the use of SGLT2 inhibitors based on EMPAREG and other studies.

MARKUS at HOMe · Jul 9, 2021 2,258 views

Joel Topf

@kidneyboy.bsky.social · Bluesky

Next week #NephJC tackles empagliflozen for renal protection from diabetic kidney disease. http://www.nejm.org/doi/full/10.1056/NEJMoa1515920#t=article

Jun 24, 2016 View post →